The prevention and treatment of coronary heart disease is a major challenge in the overall management of the patient with type 2 diabetes. Diabetic dyslipidaemia is an important risk factor and is open to therapeutic intervention. However, as yet there are no primary or secondary coronary heart disease prevention trials of lipid-lowering therapy reported in diabetic populations. In this review, on-going clinical trials of lipid-lowering therapy in specific diabetic populations will be described.

Type

Journal article

Journal

Curr Opin Lipidol

Publication Date

12/2000

Volume

11

Pages

621 - 626

Keywords

Anticholesteremic Agents, Arteriosclerosis, Atorvastatin Calcium, Clinical Trials as Topic, Coronary Disease, Diabetes Mellitus, Type 2, Fenofibrate, Heptanoic Acids, Humans, Hyperlipidemias, Hypolipidemic Agents, Pyrroles, Risk Factors